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Abstract: Nanobodies are well-established targeting ligands for molecular imaging and therapy.
Their short circulation time enables early imaging and reduces systemic radiation exposure. However,
shorter circulation time leads to lower tracer accumulation in the target tissue. Cell-penetrating
peptides (CPPs) improve cellular uptake of various cargoes, including nanobodies. CPPs could
enhance tissue retention without compromising rapid clearance. However, systematic investigations
on how the functionalities of nanobody and CPP combine with each other at the level of 2D and 3D cell
cultures and in vivo are lacking. Here, we demonstrate that conjugates of the epidermal growth factor
receptor (EGFR)-binding nanobody 7D12 with different CPPs (nonaarginine, penetratin, Tat and hLF)
differ with respect to cell binding and induction of endocytosis. For nonaarginine and penetratin
we compared the competition of EGF binding and performance of L- and D-peptide stereoisomers,
and tested the D-peptide conjugates in tumor cell spheroids and in vivo. The D-peptide conjugates
showed better penetration into spheroids than the unconjugated 7D12. Both in vivo and in vitro,
the behavior of the agent reflects the combination of both functionalities. Although CPPs cause
promising increases in in vitro uptake and 3D penetration, the dominant effect of the CPP in the
control of biodistribution warrants further investigation.
Keywords: cell-penetrating peptides; molecular imaging; nanobody; spheroids; tumor target-
ing; biodistribution
1. Introduction
Nanobodies are soluble antigen binding proteins derived from the variable part of
the single heavy chain of camelid antibodies (VHH) [1]. They are approximately ten times
smaller than a full monoclonal antibody (about 15 kDa), very stable and easy to produce.
Furthermore, they can be generated and selected to bind a wide range of epitopes, with
affinities in the nanomolar range. Nanobodies can also recognize concave epitopes, which
are structurally inaccessible for antibodies [2,3]. Due to their small size, they clear faster
from the circulation than antibodies. In addition, in vitro and in vivo results demonstrate
that they penetrate deeper into tissue, reaching a more homogeneous distribution through-
out the whole tumor mass [4,5]. These characteristics make nanobodies excellent tools for
molecular imaging, targeted therapy and the combination thereof, named theranostics.
Their potential as imaging and/or therapeutic tracers has already been shown for a number
of targets [6].
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However, there are challenges to overcome. Fast blood clearance provides good
contrast at early timepoints, but narrows the time window in which a nanobody can
reach the target tissue. For optimal imaging, clearance and tissue uptake should be
in balance. In preclinical tumor models, specific tumor accumulation of nanobodies is
typically ≤10%ID/g at the optimal timepoint [7–9], compared to the 30%ID/g or higher of
some monoclonal antibodies [5,10,11]. Several approaches that increase tissue targeting also
increase the molecular weight, shifting the balance back to increased plasma half-lives, and
possibly compromising tissue penetration. One example is the development of nanobody-
based multispecific or multivalent tracers [12,13]. Other modifications that increase the
plasma half-life are addition of albumin-binding domains and PEGylation [14–18].
Ideally, rapid and specific tissue uptake should be enhanced without increasing the
molecular weight, to preserve fast clearance of an unbound nanobody. One strategy is to
engineer the nanobody sequence itself, by substituting amino acids at certain positions of
the original sequence to add positive charges to the surface [17]. This approach has also
been applied to antibodies [18]. However, this “cationization” or “re-surfacing” increases
retention in all organs and can also reduce affinity, counteracting specific targeting and
augmenting radiation exposure of healthy tissues.
In order to enhance specificity, addition of tumor targeting peptides has also been
explored. These peptides are only a few amino acids long and thus do not considerably
change the molecular weight of the targeting agent. In this direction the addition of an
RGD or iRGD peptide, which targets integrin αvβ3, has attracted considerable atten-
tion [19–21]. iRGD addition has also been pursued for a nanobody and an antibody [19,22].
CendR peptides, or cleavable forms of them, are other examples. The CendR motif binds
to Neuropilin-1, and this interaction helps endocytosis [23]. However, integrins and
Neuropilin-1 are also expressed in healthy tissues.
Cell-penetrating peptides (CPPs) induce cellular uptake in a receptor-independent
manner. Since their discovery in the 90s [24,25] they have been employed to mediate
uptake of oligonucleotides [26], peptides [27], antibodies [28,29] and nanoparticles [30,31].
Therefore, CPPs are also good candidates to enhance cellular uptake and tissue retention of
tumor targeting agents.
Previously, we conjugated the anti-EGFR nanobody 7D12 to a CPP derived from
human lactoferrin (hLF) [32]. This conjugate was taken up through endocytosis to a higher
extent than the unconjugated 7D12 [33]. This uptake was independent of EGFR activation,
demonstrating synergy between receptor targeting by the nanobody and internalization
triggered by the CPP. Moreover, we recently found that CPPs rapidly penetrate into
tumor cell spheroids [34]. The capacity to penetrate was more pronounced for the CPP
nonaarginine (R9) than for the amphipathic penetratin (Pen) peptide and D-peptides were
superior to their L-peptide counterparts. Furthermore, R9 enhanced spheroid penetration
of elastin-like polypeptide nanoparticles [30].
Both observations combined suggest that nanobody-CPP conjugates have the potential
to specifically target, penetrate and be retained in tumors in vivo. However, to exploit
this potential fully, more mechanistic insight is needed. As CPPs differ in terms of charge,
secondary structure and amphiphilicity, it is plausible that also the respective nanobody-
CPP conjugates will interact differently with cells and tissues. In the context of theranostics,
it will be of particular interest to understand to which extent the targeting functionality
can counteract the propensity of the CPP to distribute to the liver and kidneys [35,36]. To
understand the interplay between nanobody (or targeting moiety) and CPP, we followed
up on our previous results by conjugating 7D12 to four different CPPs: hLF, R9, Tat
and Pen. R9, Tat and hLF are cationic CPPs that all show comparable cellular uptake
characteristics [37], while Pen is more amphipathic.
We assessed binding and uptake of the conjugates on cell monolayers, also in the
presence of the natural EGFR ligand EGF. Furthermore, for the penetratin and nonaarginine
conjugates (7D12-Pen and 7D12-R9), we probed EGFR phosphorylation, and binding and
uptake at low concentrations of radiolabeled conjugate. We included conjugates of the
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D-peptide variants in the comparison, and evaluated their 3D penetration and retention in
cell spheroids and in vivo biodistribution in mouse models. Each CPP enhanced binding
and internalization of 7D12 in a distinct manner. For the conjugates tested, CPPs enhanced
retention and penetration into SKOV3 spheroids. However, this did not translate into
higher tumor uptake in an in vivo model.
2. Results
2.1. Production of Nanobody-CPP Conjugates
The recombinantly expressed and purified 7D12 anti-EGFR nanobody was coupled to
either the fluorophore Atto532 or the chelator DTPA via maleimide chemistry (Figure 1A),
and to each CPP via Sortase A-mediated transpeptidation (Figure 1B, CPP sequences in
Table S1). All conjugates were pure and were in the expected size range as confirmed by
SDS-PAGE stained with Coomassie brilliant blue (Figure 1B,C) and ESI-ToF mass spectrom-
etry (Table S2 and Figure S1). Observed masses were very close to the calculated masses.
Figure 1. (A) Schematic representation of coupling of the Atto532 dye or DTPA chelator to the unpaired cysteine in 7D12
using maleimide chemistry and (B) sortase A-mediated transpeptidation for coupling of the various CPPs to the C-terminus
of 7D12. (C) Coomassie brilliant blue-stained SDS-PAGE gel of 7D12-Atto532 conjugates; 1: 7D12-Atto532; 2–3: reaction
mixtures: (2: 7D12-Atto532-Pen, 3: 7D12-Atto532-hLF) 4–7: purified conjugates (4: 7D12-Atto532-R9, 5: 7D12-Atto-532-Pen,
6: 7D12Atto532-Tat, 7: 7D12-Atto532-hLF). Slight differences in band height are due to different molecular weights of
the peptides. (D) Coomassie brilliant blue-stained SDS-PAGE gel of 7D12-DTPA conjugates; 1: 7D12, 2: 7D12-DTPA,
3: 7D12-DTPA-r9, 4: 7D12-DTPA-pen. The arrow points to a small amount of Sortase A that could not be removed
with purification.
2.2. Differential Uptake of 7D12-CPP Conjugates in EGFR Expressing Cells
First, we evaluated binding and uptake of the 7D12-Atto532-CPP conjugates in A431
cell monolayers, using live-cell confocal microscopy. Conjugates were used in low micro-
molar concentrations as reported previously [33].
All nanobody variants showed endosomal uptake (Figure 2A). Visually, the presence
of endosomes was higher for 7D12-R9, 7D12-Pen and 7D12-Tat than for 7D12-hLF and
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unconjugated 7D12. Membrane localization was less intense for 7D12-Atto532-Pen and
7D12-Atto-532-hLF than for the other variants. Visual inspection suggested more vesicular
uptake in relation to the membrane-bound fluorescence for 7D12-Atto532-Pen. Total
fluorescence intensity (total cell binding) was significantly lower for 7D12-Atto532-Pen,
7D12-Atto532-Tat and 7D12-Atto532-hLF in comparison to 7D12-Atto532. Signal intensities
of 7D12-Atto532-R9 and 7D12-Atto532 were similar (Figure 2B).
Figure 2. (A) Visual comparison of the binding and uptake of the different 7D12-Atto532-CPP conjugates in A431 cells.
Upper panels: whole field of view. Lower panels: enlargements of the indicated areas. (B) Quantification of the mean
fluorescence intensity in each field of view. Data from two independent experiments, two fields of view per experiment.
Intensity values of experiment 2 were normalized to intensity values of experiment 1. However, note that for experiment 2,
the overall intensity was lower. Each dot represents a field of view and error bars indicate SD. Differences in mean pixel
intensity were analyzed with a one-way ANOVA and a post hoc Dunnett’s test comparing each 7D12-CPP conjugate to the
unconjugated 7D12. We accepted a type I error of 5% (p < 0.05). Significant differences are indicated with an asterisk.
Of the CPPs we tested, nonaarginine and penetratin differ the most in their amphi-
pathicity. Although penetratin showed an overall lower intensity and lower cell membrane
binding, the low membrane staining and high number of endosomes suggests that its
internalization was more efficient in respect to the amount of binding. In previous research,
we had observed that nonaarginine showed a faster and deeper penetration of tumor cell
spheroids than penetratin [34]. As our goal was the application of the conjugates in vivo,
for a further comparison of conjugates we selected these two peptides.
2.3. Competition of EGF Binding by 7D12-R9 and 7D12-Pen
The binding site of 7D12 on EGFR overlaps with that of the natural ligand EGF [38].
Therefore, we were interested on whether unconjugated 7D12 and the 7D12-CPP conjugates
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differed in the competition with EGF. To avoid internalization of EGFR, A431 cells were
incubated with the compounds at 4 ◦C.
In the “coincubation” experiments, cells were preincubated with nanobody or con-
jugate and EGF was added in the presence of conjugate after 30 min. 7D12-Atto532-CPP
conjugates were slightly but consistently better in competing with EGF binding compared
to 7D12-Atto532 (Figure 3A). However, none of the conjugates showed better binding
than unconjugated 7D12 in coincubation with EGF (Figure 3B). EGF has a low nanomolar
affinity for EGFR while the KD of 7D12 is in the upper nanomolar range [33,38,39]. Com-
petition with EGF may explain the smaller difference between 7D12-Pen and 7D12 in this
experiment (Figure 3B), compared with the previous one (Figure 2).
Figure 3. Signal intensity (arbitrary units) reflecting binding of biotinylated EGF (left) and the different conjugates (right) on
A431 cells. Dots represent the mean pixel intensity of a field of view. Two fields of view were taken for each of 2 independent
experiments. Error bars indicate SD. (A) EGF binding after coincubation. Cells were incubated at 4 ◦C for 30 min with
nanobody, then EGF was added to the same media. (B) Conjugate binding after coincubation. (C) EGF binding after
sequential incubation. Cells were incubated at 4 ◦C for 30 min with nanobody, then media were removed and medium with
EGF was added. (D) Conjugate binding after sequential incubation. Differences in intensity were analyzed separately for
the conjugate and for EGF, using a one-way ANOVA and a post hoc Bonferroni test comparing 7D12-R9, 7D12-Pen and
7D12 to each other. We accepted a type I error of 5% (p < 0.05). Significant differences are indicated with an asterisk.
In the “sequential incubation” experiments, cells were first incubated with 7D12 or
7D12-CPP and subsequently with EGF, in the absence of 7D12 or conjugate. Again, both
conjugates were more effective in competing for EGF compared to unconjugated 7D12-
Atto532 (Figure 3C). Notably, 7D12-Atto532-R9 led to a significantly higher reduction
of EGF binding than 7D12-Atto532-Pen. Additionally, both conjugates showed stronger
binding than 7D12-Atto532 in these conditions (Figure 3D). These results are in line with a
stronger membrane binding of 7D12-R9 compared to 7D12-Pen.
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2.4. The Effect of 7D12-R9 and 7D12-Pen on EGFR Activation
In our previous work we showed that 7D12-hLF induces receptor internalization
without activation. We assessed whether this also holds for 7D12-Atto532-R9 and 7D12-
Atto532-Pen. A431 cells were incubated with 7D12-Atto532 and each CPP-conjugate in low
serum conditions. EGF was added for the last 10 min before fixating the cells, and EGFR
phosphorylation was detected by immunofluorescence.
The conjugates reduced EGFR phosphorylation to the same extent as the unconjugated
nanobody. Compared to 7D12-Atto532, both CPP-conjugates caused a small increase in
phosphorylation in the absence of EGF stimulation (Figure 4A), however the difference was
not significant. As observed in the sequential incubation experiment at 4 ◦C (Figure 3D),
the amount of bound 7D12-Atto532-R9 conjugate was significantly higher than that of
7D12-Atto352 and 7D12-Atto532-Pen (Figure 4B).
Figure 4. (A) Fluorescence intensity (arbitrary units) of immunostaining with an anti-pTyr antibody. (B) Fluorescence
intensity of the bound conjugates. Each bar represents the mean intensity per pixel, taken from ROIs of 4 fields of view
per condition, 2 from each of 2 independent experiments (±incubation without/with EGF). Each dot represents a field of
view and error bars indicate SD. We tested the differences with a one-way ANOVA and a post-hoc Tukey’s test comparing
all conditions to each other. We accepted a type I alpha error of 5% (p < 0.05). Significant differences are indicated with
an asterisk.
2.5. Binding and Uptake of 7D12-DTPA-R9 and 7D12-DTPA-Pen and Their D-Peptide
Counterparts at Picomolar Concentrations
The proteolytic stability of D-amino acid peptides is advantageous for in vivo appli-
cations. However, we previously observed lower endosomal uptake of all D-amino acid
CPPs compared to their L-amino acid counterparts [40]. For nanobody conjugates, confocal
microscopy revealed little visual difference between L- and D-peptide pairs (Figure S2A–D).
Nevertheless, D-peptide conjugates did show lower total fluorescence (Figure S2E). Fur-
thermore, in sequential EGF incubation (as explained for Figure 3), both L- and D-peptide
conjugates inhibited EGF binding to a similar degree (Figure S2F). In view of these results,
and in preparation of in vivo experiments, we assessed binding and internalization of
radiolabeled conjugates of both L- and D-peptides.
Cells were incubated with [111In]In-DTPA-7D12, [111In]In-DTPA-7D12-R9 and [111In]In-
DTPA-7D12-Pen and their D-amino acid counterparts at an approximate concentration of
5 pM (Figure 5). The conjugates were radiolabeled with a specific activity 0.37 MBq/µg.
Purity was checked by iTLC and exceeded 90%. Interestingly, binding and internalization
differed strongly between CPPs and between the stereoisomers of one CPP.
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Figure 5. Binding and internalization assay of [111In]In-DTPA-7D12, [111In]In-DTPA-7D12-Pen and
[111In]In-DTPA-7D12-R9 using A431 and HEK293 cells. (A) A431 cells, L-peptide conjugates (B) HEK
cells (EGFR negative), L-peptide conjugates. (C) A431 cells, D-peptide conjugates. (D) HEK cells
(EGFR negative), D-peptide conjugates. Error bars show SD of three experimental replicates.
Conjugated [111In]In-DTPA-7D12 showed good binding (28.0% ± 0.2%), and inter-
nalization (6.0% ± 0.1%) in A431 cells after 1 h incubation (Figure 5A). Both binding and
internalization were completely blocked with excess of non-radiolabeled unconjugated
7D12, and there was minimal binding to negative control HEK293 cells (1.2% ± 0.04%),
confirming EGFR specificity (Figure 5B). Binding of [111In]In-DTPA-7D12-R9 to A431 cells
was notably higher compared to [111In]In-DTPA-7D12 (39.0% ± 0.7% vs. 28.0% ± 0.2%),
while internalization was not remarkably altered (7.5% ± 0.4% vs. 6.0% ± 0.1%). In contrast
to the unconjugated nanobody, binding and internalization of [111In]In-DTPA-7D12-R9
could not be blocked. Additionally, binding to and internalization in HEK293 cells was
observed (33.0% ± 2.8% and 4.8% ± 0.3%, respectively) demonstrating a prominent role of
the CPP in the cell association.
The binding pattern of the penetratin conjugate differed considerably from that
of the R9 conjugate. [111In]In-DTPA-7D12-Pen showed significantly increased binding
(39.0% ± 0.7% vs. 28.0% ± 0.2%) and internalization (17% ± 1.3% vs. 6.0% ± 0.1%) in A431
cells when compared to [111In]In-DTPA-7D12. However, in contrast to the R9 conjugate,
binding could partly be blocked by unlabeled 7D12 (20% ± 0.5% binding and 12% ± 0.2%
internalization when blocked). Increased binding to and internalization into HEK293
cells was also observed for [111In]In-DTPA-7D12-Pen (12.5% ± 1.3% and 5.7% ± 1.6%,
respectively), however, it was notably lower than for [111In]In-DTPA-7D12-R9. Remark-
ably, binding of [111In]In-DTPA-7D12-Pen to HEK cells (EGFR negative) could also partly
be blocked by unlabeled 7D12, which suggests that the nanobody contributes to some
unspecific interactions with the cell surface.
For the D-peptide conjugates, binding to A431 cells could be blocked to a larger extent
than for the L-peptides. On HEK cells, binding was less. For both cell lines, the D-peptides
internalized less than the L-peptides. Overall, these results demonstrate weaker binding of
the D-peptide conjugates, which renders the interaction more nanobody dependent.
2.6. D Tissue Penetration and Retention in Cell Spheroids
Next, we addressed the penetration of the conjugates into cell spheroids. We focused
on 7D12-r9 and 7D12-pen (the D-peptide conjugates) as r9 and pen had outperformed
their L-analogues in previous 3D experiments [34], most likely due to their enhanced
proteolytic stability.
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Next to the A431 cells, which highly overexpress EGFR, we also used SKOV3 cells
with a medium-high EGFR expression (Figure 6). Monolayers of both cell-lines were
tested in parallel for comparison with the 3D observations (Figure S3). An anti-GFP
nanobody was included as a control to single out the impact of the CPP. For this nanobody,
conjugation with penetratin was repeatedly unsuccessful. Therefore, only results for the
anti-GFP-Atto532-r9 conjugate are shown.
The 7D12-Atto532-r9 conjugate and anti-GFP-Atto532-r9 fully penetrated the SKOV3
cell spheroids. 7D12-Atto532-pen reached some cells in the core of the spheroid but
showed a brighter signal at the periphery. The unconjugated nanobodies showed almost
no retention in the spheroids, demonstrating that in the SKOV3 spheroids 3D penetration
is mostly peptide mediated (Figure 6A).
In contrast, for the A431 spheroids penetration was incomplete, with all compounds
showing strong binding to the rim (Figure 6B). However, also for the anti-GFP-Atto532-
r9 conjugate only very limited penetration was observed which can best be explained
by a higher density of the A431 spheroids in comparison to the SKOV3 cell spheroids.
Therefore, for the EGFR binding conjugates, the restriction of binding to the rim may also
be a function of cell density rather than the high density of EGFR that may act as a binding
site barrier [41]. Next to the limited penetration of the non-targeted anti-GFP-r9 conjugate
also the fact that A431 spheroids were smaller in spite of the same cell number supports
this explanation.
In SKOV3 cell monolayers, uptake of both conjugates was higher compared to uncon-
jugated 7D12 (Figure S3A). In A431 cell monolayers unconjugated 7D12 showed strong
membrane staining. The conjugates showed lower fluorescence intensity but more en-
dosomal uptake, and there were no remarkable differences between them (Figure S3B).
In all conditions, the anti-GFP-Atto532-r9 conjugate showed CPP-driven internalization,
notably without membrane staining on cell monolayers. No uptake was observed for the
unconjugated anti-GFP nanobody.
Notably, these experiments were performed at a concentration of 0.5 µM instead of
2 µM, because it was technically not possible to reach higher concentrations in the small
culture volumes of the spheroids. This could account for the smaller differences between
7D12-Atto532-r9 and 7D12-Atto532-pen, in comparison to the previous experiments.
Both in 2D and 3D, total fluorescence intensity was lower in SKOV3 cells than in
A431 cells, likely reflecting the lower receptor expression. Furthermore, the differences
between 7D12-Atto532-r9 and 7D12-Atto532-pen were clearer in SKOV3 cells than in A431
cells. This suggests that when nanobody-driven interactions were less prominent (due to
lower receptor expression) the role of the CPP gains importance. In this context, penetratin
was less active as a CPP than nonaarginine.
2.7. Biodistribution and SPECT Imaging of the r9 and Pen Conjugates In Vivo
Finally, we assessed the in vivo biodistribution of the D-peptide conjugates in nude
mice. To compare accumulation in tumors with different EGFR expression, mice were
inoculated with an A431 tumor on the left flank and a SKOV3 tumor on the right flank.
Tracer accumulation in tissues was measured at 4 h and 24 h post-injection. The complete
summary of the results can be found in Tables S3 and S4.
Overall, tracer accumulation was higher in A431 than in SKOV3 tumors (9.6% ± 2.3%
vs. 2.2% ± 0.7% for 7D12, 2.0% ± 0.4% vs. 1.1% ± 0.0% for 7D12-r9 and 5.0% ± 0.3%
vs. 2.0% ± 0.5% for 7D12-pen at 4 h post-injection), and it was higher at 4 h than at
24 h post-injection (4.8% ± 0.4% for 7D12, 1.2% ± 0.2% for 7D12-r9 and 2.7% ± 0.7% for
7D12-pen in A431 tumors). Unconjugated [111In]In-DTPA-7D12 showed the highest tumor
uptake (Figure 7). Bigger tumors accumulated more tracer in absolute values, but the
variability in uptake did not depend on tumor size when uptake was corrected for organ
weight (Figures S4 and S5). [111In]In-DTPA-7D12-pen showed higher tumor accumulation
than [111In]In-DTPA-7D12-r9. In line with the results of the binding and uptake assays,
tumor accumulation of [111In]In-DTPA-7D12-pen was more efficiently blocked than that
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of [111In]In-DTPA-7D12-r9. We observed an increase in liver uptake for both conjugates,
while kidney uptake was lower, in comparison to unconjugated 7D12.
Figure 6. Comparison of conjugate and nanobody binding and uptake in spheroids. Incubation was done for 1 h with a
concentration of 500 nM. (A) SKOV3 spheroids and (B) A431 spheroids. All spheroids were fixed and cleared to be able to
visualize the whole cell mass.
Pharmaceuticals 2021, 14, 602 10 of 22
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SD, solid bars represent the mean. (A) Biodistribution of [111In]In-DTPA-7D12-r9 in all organs.
(B) Biodistribution of [111In]In-DTPA-7D12-pen in all organs. (C) Biodistribution of [111In]In-
DTPA-7D12 in all organs. (D) Tumor accumulation for each condition and cell line. Differences
in accumulation between compounds were evaluated for each timepoint and tumor type with a
one-way ANOVA, and a Tukey’s post-hoc test. We accepted a type I alpha error of 5% (p < 0.05).
Significant differences are indicated with asterisks.
Tumor accumulation was too low and kidney and liver uptake too high to be able to
visualize the tumors on SPECT/CT. Only for [111In]In-DTPA-7D12 we could visualize a
faint signal at the A431 tumor region at 4 h post-injection (Figure 8).
Figure 8. A 3D reconstruction of the SPECT/CT images of three mice. Mice were imaged post-mortem
4 h after injection of the tracer. The blue arrow points at the signal detected in the A431 tumor.
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3. Discussion
The goal of this study was to gain a thorough understanding of how different CPPs
affect the interaction of a nanobody with cells and tissues. For this purpose, we conjugated
the well-characterized anti-EGFR nanobody 7D12 to a set of well-established CPPs. We also
addressed the impact of the stereochemistry of two of the CPPs. Importantly, we combined
semiquantitative imaging and quantitative radioactivity-based techniques and went from
simple in vitro monolayer models to in vivo models.
In comparison to the unconjugated nanobody, only 7D12-R9 showed the same overall
intensity in fluorescence microscopy. 7D12-Pen, 7D12-Tat and 7D12-hLF showed lower total
intensity, although visual examination showed high endocytosis of 7D12-Pen and 7D12-Tat.
7D12-R9 showed very good cell association, and 7D12-Pen showed high endocytosis even
with lower membrane staining. These results led to the hypothesis that penetratin induces
rapid internalization while nonaarginine induces more long-lasting membrane interaction.
Notably, the results in the subsequent experiments were consistent with this hypothe-
sis. In binding assays at low concentrations, an excess of unlabeled nanobody blocked the
binding of penetratin conjugates more strongly than that of the nonaarginine conjugates,
but penetratin conjugates had a stronger capacity to internalize. The results of co-incubation
experiments with EGF were along the same line. Higher amounts of R9 remained bound
to the cells, thereby blocking EGF binding more effectively than unconjugated 7D12 and
7D12-Pen (Figure 3). Both nonaarginine and penetratin are cationic CPPs, but the former is
arginine rich while the latter is amphipathic [42]. For tetrameric CPP-conjugated antibodies,
highly cationic CPPs triggered slightly more uptake than amphipathic ones [28], while the
7D12-nonaarginine showed more surface binding, but not more uptake, compared with
the 7D12-penetratin ones.
In spite of the higher internalization and slightly better EGF competition, 7D12-R9
and 7D12-Pen were not better than the unconjugated 7D12 in reducing EGFR activation.
This is in contrast with the results obtained for the 7D12-hLF conjugate [33]. Although
it would have been of added value, reduction of EGFR activation is not a requisite for
the improvement of theranostic compounds, which is the long-term goal of the work
presented here.
The protease resistance of D-peptides can be advantageous for in vivo applications [43].
Therefore, we compared the conjugates of the D- and L-amino acid CPPs. Confocal mi-
croscopy and radioactivity-based assays revealed similar uptake and binding patterns
for D- and L-conjugates, albeit total intensity and retained percentage were lower for the
D-peptide conjugates. Importantly, lower cellular uptake of the D-peptide variants had
been observed before for unconjugated CPPs [40]. This provides evidence that the L- and
D-CPPs differ in their interactions with the cell surface. However, the molecular basis for
these differences is not clear. Further research should elucidate whether these differences
relate to the glycocalyx, the lipid bilayer or cell surface proteins. In spite of the lower
cell interaction, given protease resistance, similar overall behavior for the conjugate and
good 3D penetration, we considered that the D-peptide conjugates were preferable for
experiments in vivo.
By comparing binding and uptake in A431 cells with those on SKOV3 cells, which
express EGFR to different levels, we gained information on the relative contribution
of nanobody-mediated receptor binding and CPP-mediated interactions. On SKOV3
monolayers 7D12-r9 showed clear membrane staining. In contrast, 7D12-pen was almost
only present in vesicular structures, pointing to a much weaker membrane binding. On
A431 monolayers both conjugates were found on the membrane and in vesicles. This
observation, and the comparison to the anti-GFP conjugates, demonstrates that in A431
cell monolayers the membrane interaction is mostly attributable to the nanobody. For
SKOV3 cells, such a clear distinction was not possible, as 7D12-r9 showed membrane
staining but 7D12-pen did not. In spheroids, differences were bigger between cell lines,
than between conjugates.
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Altogether, the abovementioned results point towards a more prominent role of the
nanobody-mediated interaction when receptor expression is high, while there is a greater
influence of the CPP at lower receptor expression. Nevertheless, the CPP retains the
capacity to induce endosomal uptake.
In vitro, penetration of the tracers was better in the SKOV3 spheroids than in A431
spheroids, and both conjugates performed better than unconjugated 7D12. In vivo, uptake
was higher in A431 tumors, and unconjugated 7D12 showed the highest accumulation.
This discrepancy might be explained by the overexpression of EGFR in A431 cells. The high
fluorescence intensity at the rims of the A431 spheroids suggests that even if penetration
is incomplete, which we have not investigated in vivo, the presence of high numbers of
receptors at the area that is reached still causes a high overall accumulation. A possible
deeper penetration in SKOV3 tumors does not compensate for the lower amount of receptor,
in terms of tracer accumulation. Relative tracer uptake did not depend on tumor size
(Figures S4 and S5). Smaller tumors did not accumulate more tracer than bigger ones,
which would be expected if bigger tumors showed incomplete tracer penetration or a
necrotic core. Furthermore, liver sequestration of the conjugates points towards dominance
of CPP-driven tissue distribution in the in vivo context.
For both conjugates we observed increased liver and spleen uptake, and a reduction of
kidney uptake. However, contrary to the observations made for an anti-HER2 affibody [44],
the C-terminal His-tag present in unconjugated 7D12 did not lead to liver uptake. Interest-
ingly, the kidney uptake of all three tracers was slightly reduced by an excess unlabeled
nanobody. Labeled and unlabeled nanobody could be competing for active reabsorption at
the proximal tubule, which has been observed by others for 7D12 [45].
Tumor visualization by SPECT/CT was only possible with 7D12 in A431 tumors,
where tracer uptake was close to 10%ID/g. Tumors with lower uptake could not be
visualized with the same settings. Others have been able to visualize tumors with only
5%ID/g nanobody uptake, but the kidney signal in the images presented appears out of
scale [46]. In a clinical setting, this could pose problems in the visualization of lesions that
are close to these organs. Optimization of timepoint and dose and blockade of unspecific
effects by coadministration of positive amino acids or peptides could help reduce kidney
accumulation of the tracer [47]. Nevertheless, high uptake in the liver would remain
problematic due to high background, the possibility that it acts as a sink, and the increase
in radiation exposure of the organ itself.
To our knowledge, this is first stepwise exploration of nanobody-CPP conjugates from
in vitro to in vivo. So far, nanobody-CPP conjugates have been studied as cell biology
tools [48] or as intracellular agents to block EGFR activation [49]. We have confirmed that
nanobody-CPP conjugates can improve cell binding and internalization in vitro, both in 2D
and 3D, and at different concentration ranges. However, in vivo, both tested CPPs showed
a surprising extent of dominance over the functionality of the conjugate, redirecting it to
the liver and counteracting a potential benefit of the CPP on tumor accumulation. Liver
accumulation tends to be high for unconjugated CPPs [36] and no major changes were
achieved by incorporation of targeting ligands [35]. However, a single-chain antibody
conjugated to penetratin and Tat did not show increased liver targeting after 8 or 24 h, and
showed moderately higher tumor retention [50]. This indicates that when the contribution
of the CPP and that of the ligand are in the right balance, CPP conjugates do have the
capacity to improve targeting.
Evidently, the interplay between nanobody, CPP and the cellular environment is an
intricate balance that we are just beginning to understand. Therefore, more systematic com-
parisons of CPP targeting conjugates, as has been done for CPPs in other contexts [51–53],
are needed to get a deeper understanding. The use of well-characterized ligands, like
nanobodies, provides an excellent opportunity to compare more than one conjugate to an
established “model” (e.g., the unconjugated nanobody). Advances like activatable CPPs
could be useful in avoiding off-target accumulation [54–56], but will need to be evaluated
as conjugates in the in vivo setting. In conclusion, CPPs can modify the interactions of tar-
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geting ligands with organs and tissues, while maintaining fast clearance. To exploit the full
potential of CPP conjugates, the bottleneck will be to further define the structure-activity
relationships of targeting agent and CPP that balance ligand- and CPP-driven interactions.
4. Materials and Methods
4.1. Nanobody Expression and Purification
The 7D12 nanobody with a periplasmic localization signal (PelB), an LPETG sortase-
recognition site, an 8xHis and a VSV tag was expressed as described previously [33]. ER2566
bacteria were grown overnight in LB medium with 1% glucose and 100 µg/mL ampicillin.
Then, bacterial cultures were diluted to an OD600 of 0.1 in 2xTY buffer with 5% glycerol
and 50 µg/mL ampicillin and grown to log phase (OD600 = 0.6–0.8). Protein expression
was induced with 0.5 mM isopropyl β-D-thiogalactoside (IPTG) at 30 ◦C for 3–4 h. Bacterial
pellets were diluted in 0.2 M TRIS buffer, with 20% sucrose, EDTA and protease inhibitor
(Roche), pH 8 and the periplasmic fraction was collected upon centrifugation. The pellet
was incubated once more in the same buffer, with additional MgSO4, to chelate the EDTA
(which could interfere with the subsequent IMAC purification). IMAC purification using
NiNTA-sepharose was performed as described before [33]. Imidazole used for elution
was removed by overnight dialysis in a 3.5 kDa membrane against 50 mM Tris/HCl
pH 7.5, and 150 mM NaCl, or it was removed together with TCEP using a 10 kDa MWCO
centrifugal unit (Amicon, Millipore, Darmstadt, Germany), after reduction of the cysteines
for subsequent maleimide-dye coupling.
The control anti-GFP nanobody (sequence kindly provided by Prof. Dr. Heinrich Leon-
hardt, LMU München) was cloned into the same expression vector as 7D12 (periplasmic
expression), and into the pQiq cytoplasmic vector. For the periplasmic expression vector,
the same procedure was used as described above. For the cytoplasmic vector, expression
and purification were performed as for Sortase A (see below). Both protocols yielded
functional nanobody.
4.2. WT Sortase A Expression
Glycerol stocks of transformed ER2566 bacteria were obtained as explained previ-
ously [34] and grown overnight as described above. The overnight culture was diluted to
an OD600 of 0.1 in 2xTY supplemented with 50 µg/mL ampicillin and incubated at 37 ◦C
at 150 rpm. At OD600 ≥ 0.6, the protein expression was induced with 0.5 mM IPTG at
30 ◦C for 3 h. Cells were harvested by centrifugation at 3500 rpm for 20 min at 4 ◦C. The
cell pellet was then resuspended in 50 mM Tris-HCl, pH 7.5 and 150 mM NaCl and lysed
by sonication at 4 ◦C. The sonicated lysate was centrifuged at 6000 rpm for 15 min at 4 ◦C.
Sortase A contained a His-tag and was purified from the supernatant via IMAC, following
the same protocol as for the nanobodies.
4.3. Dye and Chelator Coupling to the Nanobody
7D12-C-LPETG-Hisx8-VSV was incubated with 20 mM TCEP for 20 min at room
temperature. Excess TCEP was removed by exchanging the buffer with reaction buffer
(20 mM phosphate buffer, 150 mM NaCl, 5 mM EDTA and pH 7.5) using a 10 kDa
MWCO centrifugal unit (Amicon, Millipore, Darmstadt, Germany). After this step, pro-
tein concentration was measured again and maleimide Atto-532 (Sigma-Aldrich, Darm-
stadt, Germany) or maleimide-DTPA (Chematech, Dijon, France) was added to the solu-
tion at a protein:dye/chelator molar ratio of 1:3. This mixture was incubated for 2 h at
room temperature.
The Atto532 conjugates were dialyzed overnight against a 50 mM TRIS buffer with
150 mM NaCl, pH 7.4. The DTPA conjugates were dialyzed for five days against PBS
with Chelex-100 resin (Bio-Rad, Hercules, CA, USA), changing the PBS every day. After
dialysis, the concentration of conjugates was measured with a Nanodrop device. For
determination of protein concentrations, absorbance of the dye at 280 was corrected for
and the concentrations of both protein and dye were calculated based on their absorbances
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and extinction coefficients. Extinction coefficients at 280 nm: 7D12: 35,535, 7D12-R9 and
7D12-r9: 34,045, 7D12-Pen and 7D12-pen: 45,045, 7D12-hLF: 39,670 and 7D12-Tat: 34,045
and at 532 nm: Atto-532: 115,000 M-1 cm−1.
4.4. Coupling of CPPs to Nanobodies Via Sortase A Transpeptidation
GGG-CPPs (R9, Penetratin, Tat, hLF, r9 and D-penetratin) where GGG stands for
an N-terminal triglycyl moiety were purchased from EMC microcollections (Tübingen,
Germany). Sequences can be found in Table S1. Lower case abbreviations refer to peptides
containing D-amino acids. Purified precipitates of the peptides were reconstituted in
Milli-Q at a concentration of 3 mM and stored at −20 ◦C.
Sortase A-mediated reactions to couple CPPs to 7D12 were performed in a maximum
volume of 2 mL, with reagents at the following concentrations: 20 µM 7D12, 50 µM Sortase
A and 500 µM GGG-CPP in 50 mM TRIS buffer with 150 mM NaCl and 20 mM CaCl2,
pH 7.4. The mixture was incubated at 37 ◦C for 3 h with constant agitation at 450 rpm.
Cleaved G-His8x-VSV fragments, Sortase A and unreacted nanobody were removed by
reverse IMAC, as all the unwanted products contained a His-tag, while the coupled
nanobodies lost it by cleavage at the LPETG Sortase A-specific site.
After reverse IMAC, unreacted GGG-CPP and calcium ions were removed by dialysis
or filtration through a 10 kDa MWCO centrifugal unit, against a HEPES-buffered saline
(25 mM HEPES, 0.75 mM Na2HPO4, 70 mM NaCl and pH 7). The concentration of the final
products was measured as described. Conjugates were snap-frozen and stored at −80 ◦C.
The same procedure was performed for the anti-GFP control nanobody, with two
modifications: The pI of this nanobody is predicted to be 7.09. To avoid precipitation of the
nanobody, buffers were set at pH 6.5. To compensate for a lower activity of Sortase A at
this lower pH, the reaction mix was incubated overnight instead of for 3 h.
4.5. Mass Spectrometry
The CPP conjugates were analyzed by UPLC-MS. UPLC-MS was performed on a
XEVO QTOF G2 Mass Spectrometer (Waters, Herts, United Kingdom), with an Acquity H-
class solvent manager, FTN-sample manager and TUV-detector. The system was equipped
with a reversed phase C18-column (Waters, acquity PST 130 A, 1.7 µm 2.1 mm × 50 mm
i.d.), column temperature 40 ◦C. Mobile phases consisted of 0.1 v/v% formic acid in H2O
(buffer A) and 0.09 v/v% formic acid in 10 v/v% H2O in CH3CN (buffer B). FTN-purge
solvent was 5 v/v% CH3CN in H2O. Absorption was measured at 220 nm. For the Atto532-
conjugated compounds, a linear gradient of 20–80% buffer B in buffer A over 10 min was
used. The DTPA-conjugates were analyzed with a linear gradient of 10–55% buffer B in
buffer A over 15 min. Mass was measured in positive sensitivity mode; for a mass range
between 400 and 1600 Da or 800 and 1600 Da for DTPA- or Atto532-conjugated nanobodies,
respectively. Mass Spectra were deconvoluted using the MaxEnt3 software (Waters), and
plotted in R.
4.6. Cell Culture
All media were supplemented with 10% fetal calf serum (PAN Biotech, Aidenbach,
Germany) and glutamax (Thermofisher Scientific, Waltham, MA, USA). All cell lines were
incubated at 37 ◦C in 5% CO2 in a humidified atmosphere.
A431 cells were maintained in DMEM (Thermofisher Scientific) supplemented as
indicated. For microscopy experiments, cells were seeded at a density of 30,000 cells
per well a day before the experiment, or 15,000 cells per well two days before, in 8-well
microscopy slides (Ibidi, Gräfelfing, Germany). For binding and internalization assays
with radioactive compounds, A431 cells were seeded in 6-well plates at a density of
300,000 cells/well, 2 days before the experiment.
HEK293T cells (ATCC) were maintained in DMEM, supplemented as indicated. For
microscopy experiments, HEK293T cells were seeded at a density of 60,000 cells per well one
day before the experiment, or 30,000 cells two days before. For binding and internalization
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assays with radioactive compounds, HEK293T cells were seeded in 6-well plates at a density
of 300,000 cells/well, 2 days before the experiment.
SKOV3 cells were maintained in DMEM (Thermofisher Scientific) supplemented
as indicated. For microscopy experiments, SKOV3 cells were seeded at a density of
40,000 cells/well one day before the experiment, or 20,000 cells/well two days before in
8-well microscopy slides (Ibidi).
4.7. Uptake Experiments in Life Cells (Confocal Microscopy)
A431 cells were incubated for 1 h with 2 µM 7D12 and 7D12-CPP Atto532-labeled
constructs, unless indicated otherwise. For the lysotracker experiments, cells were incu-
bated with lysotracker Deep Red (Thermofisher Scientific) for 30 min at a concentration
of 75 nM. All incubations were performed in phenol red-free DMEM, supplemented with
10% FCS and glutamax, and at 37 ◦C. After incubation cells were washed once and fresh
phenol red-free medium with 20 mM HEPES was added to the wells. Cells were im-
aged with a laser scanning confocal microscope (LSCM) (SP5 or SP8, Leica Microsystems,
Mannheim, Germany) on a temperature-controlled stage at 37 ◦C. We used an HCX PL
APO 63 × 1.2 water immersion lens. On the SP5 system, the argon ion laser line at 514 nm
was used for excitation, and emission was collected between 540 nm and 600 nm. For the
SP8 system, a white light laser was used at 532 nm and emission was collected over the
same range.
4.8. Detection of EGF Binding
For coincubation experiments with EGF, A431 cells were incubated in DMEM with
2 µM nanobody, conjugate or none (control) for 30 min at 4 ◦C, and then 16.5 nM EGF-
biotin (Thermofisher Scientific) was added to the same media and incubated for another
30 min at 4 ◦C. Subsequently, cells were incubated with 2 µg/mL streptavidin-Alexa568
(Thermofisher Scientific) at 4 ◦C and for 30 min.
For the sequential incubation experiments, A431 cells were incubated first with 2 µM
nanobody, conjugate or none for 30 min at 4 ◦C. Subsequently, media were removed
and medium with 16.5 nM EGF-biotin was added and incubated for 30 min at 4 ◦C.
Finally, medium was changed again to incubate cells with 2 µg/mL streptavidin-Alexa568
(Thermofisher Scientific) at 4 ◦C for 30 min. Cells were washed 1× with PBS and fixed
with a chilled solution of 2% paraformaldehyde (PFA) for 10 min. After fixation, fresh
PBS was added to the cells and LSCM imaging was performed. We used an HCX PL APO
63 × 1.2 water immersion lens, the nanobody was detected using the same parameters as
stated above and EGF was imaged using a DPSS laser of 561 nm with detection of emission
between 580 and 620 nm.
4.9. pTyr1068 Staining
Cells were incubated with 2 µM nanobody, conjugate or none in DMEM with 0.5%
FCS for 1 h at 37 ◦C, then stimulated with 16.5 nM EGF-biotin (Thermofisher Scientific)
for 10 min at 37 ◦C, washed 1× with PBS and fixed with 2% PFA at room temperature for
10 min. After fixation, cells were washed 1× and incubated for 20 min at RT with a 100 nM
glycine solution in PBS to quench the free aldehyde groups of the PFA. After one wash
with PBS, cells were permeabilized with 0.1% Triton X-100 (Sigma) in PBS for 20 min at RT.
Blocking was done for 20 min at RT with 3% BSA in PBS, and antibodies were diluted
in the same buffer. Mouse anti-pTyr1068 primary antibody (clone D7A5, Cell Signaling
Technology) was diluted 1:800 and incubated for 1 h at RT. Alexa647-conjugated anti-mouse
secondary antibody (Life Technologies) was diluted 1:500 and incubated for 1 h. Cells were
washed 1× with blocking buffer between the two incubations and after incubation with
the secondary antibody. After the washing steps, PBS was added and LSCM imaging was
performed. We used an HCX PL APO 63 × 1.2 water immersion lens. pTyr was imaged
using an HeNe laser of 633 nm with detection of emission between 640 and 690 nm.
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4.10. Spheroid Culture, Incubation and Optical Clearing
Spheroids were obtained using the hanging drop method. SKOV3 and A431 cells
were diluted in DMEM media with 2% v/v methylcellulose. On top of the lid of a petri
dish, 30 µL drops (containing 15,000 cells per drop) were pipetted. The lid was flipped and
placed on top of the dish bottom, which contained a small volume of PBS to prevent the
spheroids from drying out. The dish with the hanging drops was incubated at 37 ◦C, 5%
CO2 in a tissue culture incubator.
Incubation with 7D12 and conjugates (0.5 µM for 1 h) was performed in the drops
once the spheroids had reached a sufficient size (typically after 3 days). The lid was flipped
over and solutions containing the conjugate were carefully pipetted into the drop (pipetted
volume did not exceed 10 µL). The lid was flipped again and placed over the bottom
with PBS to incubate as usual at 37 ◦C. After incubation, spheroids were harvested into
microcentrifuge tubes with PBS, by carefully sucking up the drops with a 1 mL pipette tip.
The spheroids sunk to the bottom, PBS was removed and PBS with 4% PFA was added. The
spheroids were kept in this solution, in slight agitation, for at least 40 min at RT. Once fixed,
two to six spheroids of the same experimental condition were embedded in one collagen
drop. Each collagen drop was placed in a well of an Ibidi 8-well microscopy slide, and the
slide was kept for 40 min at 37 ◦C to allow collagen polymerization. Collagen embedding
prevents movement of the spheroids during imaging.
Clearing of the collagen-embedded spheroids was done by incubating them in serial
dilutions of fructose in Milli-Q with 0.5% v/v thioglycerol (which prevents the fructose
solution from turning brown). This is an adaptation of the SeedB protocol [57]. Incubation
was done for at least 3 h in 28.75% fructose, 5 h in 57.5% fructose and overnight in 115%
fructose. Spheroids were imaged in the collagen drops immersed in the 115% fructose
solution by LSCM. We used a 20× lens, and the same laser settings as for the 2D imaging
of the Atto532-labeled nanobodies.
4.11. Radiolabeling of the 7D12 Conjugates and Quality Control
7D12-DTPA, 7D12-DTPA-Pen, 7D12-DTPA-R9 and the D-peptide conjugates were
incubated with [111In]InCl3 (Curium, Petten, The Netherlands) and twice the volume of
metal free 0.5 M 2-(N-morpholino)ethanesulfonic (MES) buffer, pH 5.5 for 30 min at room
temperature. Labelling efficiency and radiochemical purity were determined by instant
thin-layer chromatography (iTLC) on a silica gel chromatography strip (Biodex, Shirley, NY,
USA), using 0.1 M citrate buffer pH 6.0 as the mobile phase. For in vitro studies, labelling
was performed at 0.25 MBq/µg; for in vivo studies, labelling was performed at 2 MBq/µg
for the SPECT injections (10 MBq per mouse) and at 0.2 MBq/ug for the mice, which were
only used for ex vivo biodistribution (1 MBq per mouse).
Binding and internalization assays of radiolabeled conjugates:
A431 or HEK293T cells were seeded on 6-well plates one or two days before the exper-
iment and were used once they were confluent. Conjugates were radiolabeled following
the procedure described above. Cells were incubated with 300 Bq of the conjugates in 1 mL
of 0.5% BSA in RPMI (binding buffer) for 1 h at 37 ◦C. EGFR specificity of binding was
assessed by coincubation with 50 µg unlabeled 7D12 per well. After incubation, cells were
washed twice with PBS, and the receptor-bound conjugates were retrieved by incubation
with ice-cold 0.1 M acetic acid, 154 mM NaCl and pH 2.6 for 10 min on ice. After washing
twice with PBS, cells containing the internalized conjugates were collected with 1 mL
0.1 M NaOH. Activity in both fractions was determined in a γ-counter (2480 Wizard 3”,
LKB/Wallace, Perkin-Elmer, Waltham, MA, USA). Specific binding and internalization
were calculated as a percentage of the total activity added, using solution standards.
4.12. Animals
Animal experiments complied with the Dutch and European regulations on animal
experimentation and were performed after approval of the Animal Ethical Committee of
the Radboud University Nijmegen (project number: RU-DEC-2015-0071). Female BALB/c
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nude mice, 6–8 weeks old, weighing approximately 20 g, were ordered from Charles River
Laboratories (Lárbresle, France) and were housed at the local animal facility in groups of 6,
in IVC blueline cages enriched with bedding material and one polycarbonate shelter per
cage. After 1 week of acclimatization, experiments were started. After tracer injection, some
mice were housed individually overnight to avoid fighting or cross-contamination through
radioactive material excreted in bodily fluids. Otherwise, solitary caging was avoided.
4.13. In Vivo Biodistribution and SPECT Imaging
Mice were injected subcutaneously on the right flank with 0.2 mL of SKOV3 cell
suspension containing 25,000,000 cells/mL (5,000,000 cells/mouse), and one week later on
the left flank with 0.2 mL of a cell suspension containing A431 cells, 2,000,000 cells/mouse.
When the tumors were clearly visible, mice were randomly divided into groups and the
experiment was performed.
All mice were intravenously injected with 5 µg of the corresponding radiolabeled 7D12
variant in PBS/0.5% BSA ([111In]In-DTPA-7D12 (n= 10), [111In]In-DTPA-7D12-r9 (n = 10)
or [111In]InDTPA-7D12-pen (n = 10)). Four mice per group (2 per timepoint) received
10 MBq to perform SPECT imaging. The other 6 mice in each group (3 per timepoint)
received 1 MBq. For the blocking groups, a 160–180-fold excess of unlabeled 7D12 was
co-injected. Mice were euthanized by CO2/O2 suffocation 4 h and 24 h after injection.
SPECT/CT (U-SPECT-II, MiLabs, Utrecht, The Netherlands) was performed immediately
after euthanasia. The image was acquired using a 1 mm diameter pinhole ultra-high
sensitivity mouse collimator.
Blood, tumors and relevant tissues (muscle, heart, lung, spleen, pancreas, kidney, liver,
stomach, duodenum and colon) of all animals were dissected, weighed and measured in a
γ-counter (2480 Wizard 3”, LKB/Wallace, Perkin-Elmer). The percentage injected dose per
gram tissue (% ID/g) was determined based on the cpm measured for diluted injection
mixtures (standards).
4.14. Data Analysis and Statistics
Microscopy images were processed with Fiji (ImageJ). For the 2D images we obtained
the mean fluorescence intensity of the area covered by cells. First, a region-of-interest was
created that only contained the cells. Then, an automatic threshold was applied, and a
binary image was created. The total pixel intensity in the ROI was obtained and divided by
the total number of positive pixels in the binary image. This was done in a semiautomated
manner by using a python macro.
SPECT/CT images were reconstructed using the U-SPECT-Rec software provided by
MiLabs, using an 0.4 mm voxel size, 3 iterations and 16 subsets, and visualized in Inveon Re-
search Workplace software (version 3.0; Siemens Preclinical Solutions, München, Germany).
Files containing the results of microscopy image processing or gamma counting of the
plate assays were processed in Excel, and graphs and statistical analyses were generated
in GraphPad PRISM (San Diego, CA, USA). csv files containing biodistribution results
were analyzed and plotted using R. The following packages were used: tidyverse, readxl
and patchwork.
For the biodistribution results, organs with a weight lower than the minimal weight
of the balance (0.014 g) were excluded. Outliers that could not be explained by known
technical errors were kept in both the graphs and the statistical analyses. For the statistical
analyses, values were log transformed and the difference in tumor uptake between the four
compounds was evaluated separately for each timepoint and tumor type, with a one-way
ANOVA and a Tukey’s post-hoc test. We accepted a type I alpha error of 5%. The number
of animals per group was selected assuming an SD of 10% of the mean, to reach a statistical
power of 80%.
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5. Conclusions
Conjugation to cell-penetrating peptides endows targeting ligands with novel func-
tional characteristics such as induction of cellular uptake and penetration into 3D tissues.
The balance of activities depends on multiple factors among which the nature of the CPP
and the level of receptor expression. The differences between CPPs are retained when going
from simple monolayer cultures to more complex 3D cell cultures and in vivo models, but
at the same time other functional characteristics relating to the higher level of complexity
are added. Focusing future research on the factors that balance ligand- and CPP-driven
interactions in complex settings, especially in vivo, will help exploit the full potential of
CPP-conjugates of small ligands for targeted delivery.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
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as described for Figure 3. Mean intensity in arbitrary units. Each dot corresponds to one field of
view and error bars indicate SD. Two fields of view were quantified for each of two independent
experiments. Figure S3. (A) Confocal microscopy images of live SKOV3 cells incubated with 0.5 µM
7D12-Atto532, 7D12-Atto532-r9, 7D12-Atto532-pen and control anti-GFP nanobody and its conjugate,
anti-GFP-r9. (B) Confocal microscopy images of live A431 cells incubated with 0.5 µM 7D12-Atto532,
7D12-Atto532-r9, 7D12-Atto532-pen and control anti-GFP nanobody and its conjugate, anti-GFP-
r9. Mean intensity in arbitrary units. Each dot corresponds to one field of view and error bars
indicate SD. Two fields of view were quantified for each of two independent experiments. Figure S4.
Correlation between tumor weight and absolute tracer uptake (not corrected for tissue weight).
Figure S5. Correlation between tumor weight and relative tracer uptake. Table S1. Names and
abbreviations and sequences of the CPPs used. All peptides were C-terminally amidated (-NH2).
Table S2. Theoretical and found masses of the various conjugates as measured with ESI-ToF mass
spectrometry. Table S3. Biodistribution results (%ID/g) 4 h after injection. Table S4. Biodistribution
results (%ID/g) 24 h after injection.
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